Clinical research
The Phase III trial on a potential treatment for mild-to-moderate COVID-19 symptoms by Merck and Ridgeback Biotherapeutics showed promise in preventing hospitalizations and death.
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
Ferring Pharmaceuticals today announced positive results across all five of its prospective trials for a live biotherapeutic designed to reduce recurrent C. difficile infection (rCDI).
Indianapolis-based Eli Lilly presented data from two tirzepatide sub-studies at the 57th European Association for the Study of Diabetes (EASD) Annual Meeting.
LIVMARLI is indicated for ages one year and older and will now be accessible to patients with a prescription through Mirum Access Plus. Here’s more about it.
EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.
As the 10th annual IDWeek (Infectious Disease Week) Conference begins, treatments aimed at COVID-19 will certainly dominate the program.
Qulipta is the first calcitonin gene-related peptide (CGRP) receptor antagonist specifically developed for this indication.
The Phase II trial, VLA150202, evaluated the safety and immunogenicity of VLA15 on 246 healthy adults aged 18 to 65 years old across the United States.
Intra-Cellular Therapies published its Study 404 Phase III trial of lumateperone as monotherapy for major depressive episodes associated with bipolar I or bipolar II disorder.
PRESS RELEASES